

Section 172(1) statement – Year Ended 31 March 2026

The company has continued to perform well during the year which is reflected by the increase in Operating Profit for the year, despite an ‘as expected’ reduction of circa 4% in overall turnover due to the managed decline of our key atrial fibrillation drug where despite volume decline we have improved gross margin in mitigation through changes in rebate structure in the year. Guided by the company's strategic drivers, the company continues to create value for customers, employees and suppliers.

As the wholly owned UK subsidiary of our parent company we strive to fulfil the overall mission of the company here in the UK. Namely,

“To contribute to the enrichment of quality of life around the world through the creation of innovative pharmaceuticals, addressing diverse medical needs.”

And its’ 2030 Vision to be an “Innovative Global Healthcare Company contributing to the sustainable development of society.”

To realize our “Purpose,” the DS group of companies aims to address the social issues that we are expected by society to solve through our business activities, such as the creation of innovative pharmaceuticals and efforts for achieving the UN’s Sustainability Development Goals (SDGs). We challenge ourselves to continuously provide innovative solutions based on our strength: Science & Technology.

The directors recognise the importance of our wider stakeholders in delivering our strategy and business sustainability. We are conscientious about our responsibilities and duties to our stakeholders under section 172 of the Companies Act 2006.